HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.

AuthorsManfred Schmitt, Fred C G J Sweep
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 45 Issue 14 Pg. 2444-6 (Sep 2009) ISSN: 1879-0852 [Electronic] England
PMID19647994 (Publication Type: Comment, Editorial)
Chemical References
  • Anthracyclines
  • Biomarkers, Tumor
  • Tissue Inhibitor of Metalloproteinase-1
  • Epirubicin
  • Cyclophosphamide
  • Peptide Hydrolases
  • Fluorouracil
  • Methotrexate
Topics
  • Anthracyclines (metabolism, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Biomarkers, Tumor (metabolism)
  • Breast Neoplasms (drug therapy, metabolism)
  • Chemotherapy, Adjuvant (methods)
  • Cyclophosphamide (administration & dosage)
  • Epirubicin (administration & dosage)
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Methotrexate (administration & dosage)
  • Peptide Hydrolases (metabolism)
  • Tissue Inhibitor of Metalloproteinase-1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: